Search Results

Return to List
Results 1–17 of 17
Title Date

Ovarian Reserve Testing

Number 618

ABSTRACT The main goal of ovarian reserve testing is to identify those individuals who are at risk of decreased or diminished ovarian reserve commonly known as DOR Although ovarian reserve testing cannot predict the end of ones reproductive years results outside the range expected for a patients a...

January 2015

PDF Format

Chronic Antithrombotic Therapy and Gynecologic Surgery

Number 610

ABSTRACT Surgery can present a management dilemma for gynecologists whose patients receive chronic antithrombotic therapy because the risk of hemorrhagic complications must be balanced against the risk of thromboembolic complications Interruption of antithrombotic therapy to reduce perioperative b...

October 2014

PDF Format

Options for Prevention and Management of Heavy Menstrual Bleeding in Adolescent Patients Undergoing

Number 606

ABSTRACT Adolescents undergoing cancer treatment are at high risk of heavy menstrual bleeding and gynecologists may be consulted either before the initiation of cancer treatment to request strategies for menstrual suppression or during an episode of severe heavy bleeding to stop the bleeding emerg...

August 2014

PDF Format

Primary Ovarian Insufficiency in Adolescents and Young Women

Number 605

ABSTRACT Primary ovarian insufficiency is the depletion or dysfunction of ovarian follicles with cessation of menses before age 40 years There is no consensus on criteria to identify primary ovarian insufficiency in adolescents and delay in diagnosis is common Health care providers who make this c...

July 2014

PDF Format

OnabotulinumtoxinA and the Bladder

Number 604

ABSTRACT In January 2013 the US Food and Drug Administration approved the use of onabotulinumtoxinA also known as Botox A for the treatment of overactive bladder thus providing another treatment option for women Symptoms of overactive bladder have been shown to significantly improve after onabotul...

June 2014

PDF Format

Tamoxifen and Uterine Cancer

Number 601

(Replaces Committee Opinion Number 336, June 2006)

ABSTRACT Tamoxifen a nonsteroidal antiestrogen agent is widely used as adjunctive therapy for women with breast cancer and it has been approved by the US Food and Drug Administration for adjuvant treatment of breast cancer treatment of metastatic breast cancer and reduction in breast cancer incide...

June 2014

PDF Format

Preexposure Prophylaxis for the Prevention of Human Immunodeficiency Virus

Number 595

Abstract Preexposure prophylaxis is defined as the administration of antiretroviral medications to individuals who are not infected with human immunodeficiency virus HIV and are at the highest risk of acquiring HIV infection In combination with other proven HIVprevention methods preexposure prophy...

May 2014

PDF Format

Ethical Issues With Vaccination for the Obstetrician–Gynecologist

Number 564

ABSTRACT Because of the growing importance of infectious disease prevention in the individual patient and the larger community it is vital that Fellows of the American College of Obstetricians and Gynecologists be prepared to navigate the practical and ethical challenges that come with vaccination...

May 2013

PDF Format

Management of Acute Abnormal Uterine Bleeding in Nonpregnant Reproductive-Aged Women

Number 557

(Reaffirmed 2015)

ABSTRACT Initial evaluation of the patient with acute abnormal uterine bleeding should include a prompt assessment for signs of hypovolemia and potential hemodynamic instability After initial assessment and stabilization the etiologies of acute abnormal uterine bleeding should be classified using ...

April 2013

PDF Format

Postmenopausal Estrogen Therapy: Route of Administration and Risk of Venous Thromboembolism

Number 556

(Reaffirmed 2015)

ABSTRACT The development of menopausal symptoms and related disorders which lead women to seek prescriptions for postmenopausal estrogen therapy and hormone therapy is a common reason for a patient to visit her gynecologist but these therapies are associated with an increased risk of venous thromb...

April 2013

PDF Format

Over-the-Counter Access to Oral Contraceptives

Number 544

(Reaffirmed 2014)

ABSTRACT Unintended pregnancy remains a major public health problem in the United States Access and cost issues are common reasons why women either do not use contraception or have gaps in use A potential way to improve contraceptive access and use and possibly decrease unintended pregnancy rates ...

December 2012

PDF Format

Access to Emergency Contraception

Number 542

ABSTRACT Emergency contraception includes contraceptive methods used to prevent pregnancy in the first few days after unprotected intercourse sexual assault or contraceptive failure Although the US Food and Drug Administration approved the first dedicated product for emergency contraception in 199...

November 2012

PDF Format

Risk of Venous Thromboembolism Among Users of Drospirenone-Containing Oral Contraceptive Pills

Number 540

(Reaffirmed 2014)

ABSTRACT Although the risk of venous thromboembolism is increased among oral contraceptive users compared with nonusers who are not pregnant and not taking hormones and some data have suggested that use of drospirenonecontaining pills has a higher risk of venous thromboembolism this risk is still ...

November 2012

PDF Format

Compounded Bioidentical Menopausal Hormone Therapy

Number 532

(Reaffirmed 2014, Replaces No. 387, November 2007 and No. 322, November 2005)

ABSTRACT Although improvement in longterm health is no longer an indication for menopausal hormone therapy evidence supporting fewer adverse events in younger women combined with its high overall effectiveness has reinforced its usefulness for shortterm treatment of menopausal symptoms Menopausal ...

August 2012

PDF Format

Misoprostol for Postabortion Care

Number 427

ABSTRACT The World Health Organization estimates that 67000 women mostly in developing countries die each year from untreated or inadequately treated abortion complications Postabortion care a term commonly used by the international reproductive health community refers to a specific set of service...

February 2009

PDF Format

Aromatase Inhibitors in Gynecologic Practice

Number 412

(Reaffirmed 2014)

ABSTRACT Aromatase inhibitors appear to be effective as an adjuvant treatment for earlystage and latestage breast cancer Their role in chemoprevention of breast cancer in highrisk patients remains to be defined Side effects of aromatase inhibitors in postmenopausal women are due to estrogenlowerin...

August 2008

PDF Format

Brand Versus Generic Oral Contraceptives

Number 375

(Reaffirmed 2015)

ABSTRACT The US Food and Drug Administration considers generic and brand name oral contraceptive OC products clinically equivalent and interchangeable The American College of Obstetricians and Gynecologists supports patient or clinician requests for branded OCs or continuation of the same generic ...

August 2007

PDF Format

American Congress of Obstetricians and Gynecologists
409 12th Street SW, Washington, DC  20024-2188 | Mailing Address: PO Box 70620, Washington, DC 20024-9998